This book begins the discourse on post-trial access to drugs in
developing countries. Underlying ethical issues in global health
inequalities and global health research serve as the context of the
debate. Due to rampant allegations of violations of rights of research
participants, especially in developing countries, it discusses the
regulatory infrastructure and ethical oversight of international
clinical research, thus emphasizing the priority of safeguarding the
rights of research participants and host populations as desiderata in
conducting clinical trials in developing countries. This is the first
book that analyzes the major obstacles of affordable access to drugs in
developing countries - patent and non-patent factors and how they can be
overcome through a middle ground approach and a new paradigm to
establish global health justice which includes national and global
health responsibilities. The book also deals extensively with all
complex aspects of the discourse on affordable access to drugs in
developing countries, including intellectual property law, international
regulations, political and cultural systems, international trade
agreements. Furthermore it contains a robust ethical debate and in-depth
analysis. The book crafts a paradigm of global health justice involving
a sliding scale of national and global responsibilities for the
realization of the right to health in general and access to drugs in
particular.